{"filings":[{"id":972676,"accession_number":"0001104659-26-072326","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2026-06-10T20:06:08+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Entrada shareholders approve plan amendments including pre-funded warrants in evergreen formulas","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. as Class II directors; 22.2M and 22.3M votes for, respectively.","Ratified Ernst & Young as independent auditor for FY 2026 with 33.1M votes for.","Approved Amendment No. 1 to 2021 Stock Option and Incentive Plan: pre-funded warrants count in evergreen share increase calculation.","Approved Amendment No. 1 to 2021 ESPP: similarly includes pre-funded warrants in share reserve formula, plus share cap of 557,524 or 1% of outstanding shares.","38.8M shares outstanding as of record date; 33.2M shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":507924,"accession_number":"0001104659-26-063325","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2026-05-18T22:32:23+00:00","items":["7.01","9.01"],"status":"ready","headline":"Entrada updates corporate presentation; no specific financial or pipeline details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing includes updated corporate presentation (Exhibit 99.1) for use in investor meetings.","Presentation dated May 2026 was furnished under Regulation FD.","No specific changes in financial guidance, pipeline milestones, or leadership disclosed in the filing excerpt.","The full presentation content was not provided in the filing text available for analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94696,"accession_number":"0001689375-26-000027","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entrada reports positive Phase 1/2 data for ENTR-601-44 in DMD; Q1 net loss $39.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort 1 of ELEVATE-44-201 met primary safety endpoint: no SAEs, no discontinuations, kidney markers normal.","Statistically significant improvement in Time to Rise velocity versus placebo (p<.05), 3.5x MCID threshold.","Dystrophin increased 2.36% over 4.00% baseline; exon skipping increased 2.31% over 2.66% baseline.","Cash, cash equivalents and marketable securities $254.9M as of March 31, 2026; runway into Q3 2027.","Q1 net loss $39.7M vs $17.3M in Q1 2025; collaboration revenue dropped to $0.9M from $20.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107273,"accession_number":"0001689375-26-000009","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada posts Q4 net loss of $39.2M; cash at $295.7M; DMD program advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.2M in Q4 2025 vs net income of $1.1M in Q4 2024; full-year net loss of $143.8M.","Cash, cash equivalents and marketable securities of $295.7M as of Dec 31, 2025; runway into Q3 2027.","DMC recommended initiating Cohort 2 of ELEVATE-44-201 at 12 mg/kg; Cohort 1 data expected Q2 2026.","ELEVATE-45-201 Cohort 1 data on track for mid-2026; ENTR-601-50 regulatory authorization in UK obtained.","Nomination of ENTR-801 for Usher syndrome type 2A; second ocular candidate expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":25421000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107272,"accession_number":"0001689375-26-000003","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Entrada reports ~$296M cash, completes DMD cohort 1, expands pipeline into ocular disease with ENTR-801","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities of ~$296M as of Dec 31, 2025; cash runway into Q3 2027.","Completed dosing of Cohort 1 in global Phase 1/2 MAD study of ENTR-601-44 (exon 44 skipping) for DMD.","On track to report ELEVATE-44-201 data from first cohort in Q2 2026; ELEVATE-45-201 data in mid-2026.","Received UK MHRA authorization for Phase 1/2 ENTR-601-50; expect global initiation by end 2026 and regulatory apps for ENTR-601-51 in 2026.","Expanded into ocular diseases: selected ENTR-801 (Usher syndrome type 2A) as first candidate; expects second candidate in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123619,"accession_number":"0001689375-25-000049","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Q3 net loss widens to $44.1M; DMD pipeline on track for data in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $44.1M for Q3 2025, compared to $14.0M net loss in Q3 2024; collaboration revenue fell to $1.6M from $19.6M.","Cash, cash equivalents & marketable securities of $326.8M extended runway into Q3 2027.","ELEVATE-44-201 cohort 1 data on track for Q2 2026; first patient dosed in ELEVATE-45-201 with cohort 1 data expected mid-2026.","Filed UK regulatory authorization for ENTR-601-50; plans to submit EU applications in H2 2026.","Vertex VX-670 (DM1) trial enrollment and dosing on track for completion in H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":24122000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140301,"accession_number":"0001689375-25-000041","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Therapeutics reports Q2 net loss of $43.1M; cash runway into Q2 2027; advances DMD trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.1M in Q2 2025 vs net income of $55.0M in Q2 2024; collaboration revenue fell from $94.7M to $2.0M.","Cash, cash equivalents and marketable securities $354M as of June 30, 2025; expected runway into Q2 2027.","First patient dosed in ELEVATE-44-201 for DMD exon 44; data from first cohort expected H1 2026.","Initiated ELEVATE-45-201 for exon 45; first patient dosing on track Q3 2025; cohort 1 data mid-2026.","Expanded leadership: Navid Khan as SVP Medical Affairs, Kiran Patki as SVP Clinical Development; Maha Radhakrishnan joined Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":22508000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157956,"accession_number":"0001104659-25-058536","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entrada Therapeutics stockholders elect three Class I directors, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Dipal Doshi (27,809,399 for, 429,248 withheld), Kush M. Parmar (24,883,797 for, 3,354,850 withheld), Mary Thistle (27,768,093 for, 470,554 withheld).","Ratified Ernst & Young LLP as independent auditor for FY2025: 30,176,125 for, 74,925 against, 8,476 abstain.","Broker non-votes on director election totaled 2,020,879 shares.","Annual meeting held virtually on June 11, 2025; 30,259,526 shares represented (quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157955,"accession_number":"0001689375-25-000027","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Entrada Therapeutics appoints Maha Radhakrishnan, M.D. to board effective June 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maha Radhakrishnan, M.D. appointed as Class III director; board expanded from 6 to 7 members.","Also appointed to Audit Committee, replacing Kush Parmar, M.D., Ph.D.; Parmar remains chairman.","Current Executive Partner at Sofinnova Investments; former CMO of Biogen (2019-2024).","Initial equity award: option to purchase 38,000 shares vesting over 3 years; annual cash fees of $40,000 + $9,000 Audit Committee retainer.","Appointment takes effect June 1, 2025; serves until 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157954,"accession_number":"0001689375-25-000022","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada reports Q1 net loss of $17.3M, gets EU clearance for DMD exon 44 trial, cuts workforce 20%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $17.3M in Q1 2025 vs net income $23.5M Q1 2024; collaboration revenue fell to $20.6M from $59.1M.","EU authorization received for Phase 1/2 MAD study (ELEVATE-44-201) of ENTR-601-44; Q2 2025 initiation on track.","Additional DMD programs: ENTR-601-45 study initiation Q3 2025; ENTR-601-50 regulatory submission H2 2025.","Workforce reduced ~20% to focus on DMD clinical pipeline and key preclinical programs; cash runway into Q2 2027 ($382.5M).","Vertex-partnered VX-670 for DM1 continues enrollment in MAD portion of Phase 1/2 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157953,"accession_number":"0001104659-25-041204","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Entrada Therapeutics restructures, reduces workforce 20% to focus on Duchenne MD candidates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved strategic plan on April 29, 2025; workforce reduction of approximately 20% effective May 2.","Estimated $2 million in total charges (severance, healthcare) primarily in Q2 2025.","Company prioritizing DMD candidates ENTR-601-44, -45, -50, -51 and ocular programs.","Anticipates cost savings to extend cash runway into Q2 2027.","Workforce reduction substantially completed by end of Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176348,"accession_number":"0001689375-25-000018","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","8.01","9.01","2.02"],"status":"ready","headline":"Entrada receives UK authorization for Phase 1/2 trial of ENTR-601-45 in DMD exon 45 skipping","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["UK MHRA and Research Ethics Committee clearance to start ELEVATE-45-201, a Phase 1/2 MAD study of ENTR-601-45.","On track to initiate the trial in Q3 2025; Part A will evaluate doses 5–15 mg/kg every 6 weeks in ~24 patients.","Second Duchenne program (after ELEVATE-44); regulatory filings also submitted in the EU with review ongoing.","Study is randomized, double-blind, placebo-controlled with a Part B for optimal dose evaluation and an OLE.","CEO states strategy to run UK/EU studies first, then share data with FDA to enable U.S. registrational studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176347,"accession_number":"0001689375-25-000009","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Q4 net income $1.1M; FDA lifts hold on ENTR-601-44; cash $420M into Q2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $1.1M vs loss $9.5M YoY; FY net income $65.6M vs loss $6.7M.","Collaboration revenue $37.4M Q4, $210.8M FY; R&D expenses $33.4M Q4.","Cash $420M as of Dec 31, 2024; runway expected into Q2 2027.","FDA lifted clinical hold on ENTR-601-44; authorized US Phase 1b MAD study for exon 44 DMD.","MHRA authorized UK Phase 1/2 study for ENTR-601-44; regulatory filings for ENTR-601-45 in UK/EU."],"consensus_eps_estimate":null,"consensus_eps_actual":1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":210782000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176346,"accession_number":"0001689375-25-000004","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on Entrada's ENTR-601-44 for DMD Phase 1b study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA authorized ELEVATE-44-102, a Phase 1b multiple ascending dose study of ENTR-601-44 in adults with DMD amenable to exon 44 skipping.","Study targets ~32 non-ambulatory and ambulatory patients; doses from 0.16 to 1.28 mg/kg every six weeks.","Company also received UK MHRA authorization for ELEVATE-44-201; global program now covers pediatric and adult patients.","Plans to initiate enrollment in first half of 2026 with seamless transition to open-label extension.","CEO cites strength of Phase 1 safety/target engagement data and unmet need in adults living with Duchenne."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176345,"accession_number":"0001689375-25-000002","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Entrada gets UK MHRA nod for Phase 1/2 trial of DMD candidate ENTR-601-44","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["UK MHRA and REC authorized ELEVATE-44-201, a global Phase 1/2 MAD study of ENTR-601-44 for DMD exon 44 skipping.","Dosing every 6 weeks across three cohorts (6-18 mg/kg); Part A safety/PK/PD, Part B efficacy.","Company on track to initiate trial in Q2 2025; regulatory filings also submitted in US and EU.","Prior Phase 1 single-dose study showed ENTR-601-44 well-tolerated with no serious adverse events.","If eligible, participants may enter an open-label extension for longer-term safety/efficacy assessment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176344,"accession_number":"0001104659-25-003755","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Entrada reports ~$420M cash; DMD pipeline advancing with multiple 2025 trial starts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash resources ~$420M as of Dec 31, 2024, extending runway into Q2 2027.","Phase 1 ENTR-601-44 data: no treatment-related AEs; dose-dependent PK/PD and statistically significant exon skipping at 6 mg/kg.","Plans to initiate Phase 1/2 MAD studies for ENTR-601-44, -45, -50, and -51 in 2025; Vertex advancing VX-670 MAD portion in DM1.","Preclinical data show dose-dependent dystrophin restoration and functional correction in DMD mouse models across franchise.","Cash and clinical updates based on preliminary unaudited estimates; year-end audit ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193204,"accession_number":"0001689375-24-000061","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Q3 net loss $14.0M; advancing DMD franchise with regulatory filings on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.0M in Q3 2024 (vs $35.5M net income in Q3 2023); revenue down to $19.6M from $43.7M.","Cash $449.3M as of Sep 30, 2024, up from $352.0M at end of 2023; funded by $100M offering and $75M milestone.","R&D expenses $31.3M (vs $22.2M) driven by DMD candidates; G&A $10.0M (vs $7.5M).","On track to submit global regulatory filings for Phase 2 trials of ENTR-601-44 and ENTR-601-45 in Q4 2024.","Vertex completed SAD and initiated MAD for VX-670 in DM1; Sethuraman promoted to President of R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":173384000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209576,"accession_number":"0001689375-24-000045","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Q2 net income $55M, positive Phase 1 data for DMD candidate ENTR-601-44","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net income of $55.0M vs net loss of $25.9M YoY; collaboration revenue $94.7M (up from $18.2M).","Completed $100M registered direct offering; cash & securities $469.7M as of June 30, 2024; runway into 2027.","Phase 1 trial of ENTR-601-44 showed dose-dependent plasma/muscle concentration and exon skipping; no serious adverse events.","Planning global Phase 2 trials for ENTR-601-44 and ENTR-601-45; regulatory filings expected Q4 2024; ENTR-601-50 filing planned 2025.","Vertex VX-670 DM1 trial enrolling; SAD portion expected to complete by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":2.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":153814000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227680,"accession_number":"0001104659-24-074130","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Entrada Therapeutics raises $100M in registered direct offering to fund pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $100M from sale of 3,367,003 shares at $14.85 and pre-funded warrants at $14.8499.","Offering led by U.S. healthcare-focused investor, two global mutual funds, and Janus Henderson.","Proceeds to fund Phase 2b trials for ENTR-601-44/45 and Phase 2 MAD trial for ENTR-601-50.","Expected closing on June 25, 2024; cash runway extended into 2027.","30-day lockup on new equity issuance and registration statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227679,"accession_number":"0001104659-24-074078","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Entrada reports positive Phase 1 data for ENTR-601-44; plans Phase 2 trials in Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No serious or drug-related adverse events; ENTR-601-44 well-tolerated across all 4 dose cohorts (0.75-6 mg/kg) in 32 healthy volunteers.","At 6 mg/kg, mean exon skipping 0.44% (range 0.3-0.65%), statistically significant vs placebo (p<0.005); muscle concentration mean 53.8 ng/g.","Plans to submit regulatory applications in Q4 2024 for Phase 2 trials of ENTR-601-44 (exon 44) and ENTR-601-45 (exon 45).","ENTR-601-50 Phase 2 trial filing expected in 2025; company sees potential for dosing intervals of at least six weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227678,"accession_number":"0001104659-24-071249","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Entrada Therapeutics shareholders approve officer liability limitation amendment and elect director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Certificate of Amendment to limit officer liability as permitted by Delaware law.","Gina Chapman elected as Class III director with 19,701,297 votes for, 101,960 withheld, 2,418,006 broker non-votes.","Ernst & Young LLP ratified as independent auditor for FY 2024 (22,210,935 for, 2,174 against, 8,154 abstain).","Certificate of Amendment filed with Delaware Secretary of State, effective June 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227677,"accession_number":"0001689375-24-000025","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Q1 net income $23.5M; Vertex $75M milestone; DMD Phase 1 final cohort dosed; cash runway to Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $23.5M vs loss ($6.7M) Q1 2023; collaboration revenue $59.1M (up from $25.3M) on Vertex $75M milestone.","Initiated dosing of 4th & final cohort of Phase 1 trial for ENTR-601-44 in DMD exon 44; data readout expected Oct 2024.","Cash, cash equivalents & marketable securities $327.4M as of Mar 31, 2024; cash runway expected through Q2 2026.","On track to submit regulatory apps in Q4 2024 for Phase 2 studies of ENTR-601-44 (DMD exon 44) and ENTR-601-45 (exon 45)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":59120000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246476,"accession_number":"0001689375-24-000014","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Therapeutics FY2023 net loss $6.7M, cash $352M; DMD Phase 1 data on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $352.0M as of Dec 31, 2023, up from $188.7M; runway through Q2 2026.","Collaboration revenue $129.0M full year (Vertex deal); net loss narrowed to $6.7M from $94.6M in 2022.","Completed dosing first three cohorts of ENTR-601-44 Phase 1 for DMD; data readout H2 2024.","Regulatory applications expected Q4 2024 for global Phase 2 of ENTR-601-44 and ENTR-601-45.","Promoted Nathan Dowden to President & COO; appointed Kevin Healy (SVP Regulatory) and Marie Rosenfeld (SVP Clinical Ops)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246475,"accession_number":"0001104659-24-000571","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Entrada Therapeutics promotes COO Nathan Dowden to President, effective Jan 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nathan J. Dowden promoted to President, retains COO role; Dipal Doshi continues as CEO.","Salary increased to $480,000/year; target bonus raised to 45%.","Granted 60,000 RSUs vesting 50% on 2nd anniversary and 50% on 3rd anniversary.","Dowden has served as COO since Nov 2019 and has 30 years healthcare sector experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263898,"accession_number":"0001104659-23-123805","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John F. Crowley resigns from Entrada board; Chapman and Parmar fill committee vacancies","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John F. Crowley resigned from Board, Audit Committee, and as Chair of Compensation Committee, effective December 5, 2023.","Resignation not due to any disagreement with the Company's operations, policies, or practices.","Board appointed Gina Chapman to Audit Committee and Kush M. Parmar, M.D., Ph.D. as member and Chair of Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263897,"accession_number":"0001104659-23-120557","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-11-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Entrada completes first two cohorts in Phase 1 for ENTR-601-44; US clinical hold remains","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed dosing of first and second cohorts in Phase 1 trial ENTR-601-44-101 in the UK.","Data from Phase 1 trial expected in second half of 2024.","FDA clinical hold on IND remains in effect; FDA declined to lift hold despite additional data.","Company plans global development for exon 44 skipping amenable DMD patients.","Cash runway expected through 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263896,"accession_number":"0001689375-23-000072","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Therapeutics Q3 net income $35.5M; initiates Phase 1 for DMD candidate ENTR-601-44","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $35.5M in Q3 2023 vs net loss of $(25.1M) in Q3 2022, driven by $43.7M collaboration revenue.","Cash, cash equivalents and securities of $353.6M as of Sep 30, 2023; runway expected through 2025.","Dosed first participant in Phase 1 trial of ENTR-601-44 for Duchenne muscular dystrophy; data expected H2 2024.","Selected third Duchenne candidate ENTR-601-50 with IND/CTA planned for 2025; preclinical data expected H1 2024.","Achieved Vertex milestone triggering $17.5M payment; entered license for ENTR-501 with Pierrepont Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":87165000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263895,"accession_number":"0001104659-23-113138","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Entrada gets $223.7M upfront from Vertex amendment; $17.5M milestone reached for ENTR-701","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $223.7M upfront payment from Vertex under amended collaboration/license agreements.","Eligible for up to $485M in future research, development, regulatory, and commercial milestones.","Achieved $17.5M milestone for preclinical IND-enabling GLP toxicology studies of ENTR-701; expected Q4 2023.","Amendments clarify milestone definitions and payment terms; other terms unchanged.","Vertex amendments executed Oct 26, 2023; Entrada shares trade on Nasdaq as TRDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281120,"accession_number":"0001104659-23-105351","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Entrada Therapeutics enters into $150M at-the-market offering agreement with Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into sales agreement with Cowen and Company for at-the-market offering of up to $150M in common stock.","Cowen will receive a commission of up to 3.0% of gross sales proceeds; Company not obligated to sell any shares.","Offering made under existing effective shelf registration statement (S-3) filed November 2022.","Shares will be sold on Nasdaq or other trading markets, subject to instructions and conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281119,"accession_number":"0001689375-23-000068","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Entrada doses first participant in Phase 1 trial of ENTR-601-44 for Duchenne MD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participant dosed in Phase 1 trial of ENTR-601-44 for DMD patients amenable to exon 44 skipping.","Trial conducted in UK; targets ~40 healthy male volunteers; endpoints include safety, PK, and target engagement.","Data from the Phase 1 trial expected in the second half of 2024.","Initiation marks Entrada's transition into a clinical-stage company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281118,"accession_number":"0001104659-23-089549","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Entrada Therapeutics appoints Gina Chapman to board effective Sept 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gina Chapman, President and CEO of CARGO Therapeutics, joins as Class III director.","Effective Sept 1, 2023; also appointed to Nominating and Corporate Governance Committee.","Initial equity grant of $500K value (32,000 shares of common stock) vesting over 3 years.","Annual director fee of $40,000 plus $4,000 for committee service; standard indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281117,"accession_number":"0001689375-23-000053","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Q2 cash $376.8M; on track to dose first participant in ENTR-601-44 Phase 1 in Sept 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $376.8M as of June 30, 2023, up from $188.7M at year-end 2022; cash runway extended through 2025.","Collaboration revenue of $18.2M in Q2 2023 (none in prior year); net loss $25.9M vs $23.2M.","Received MHRA and REC authorization for Phase 1 trial of ENTR-601-44 in healthy volunteers in UK; first dosing expected in September 2023 with data in H2 2024.","IND for ENTR-601-44 on clinical hold with FDA; update expected in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":43430000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281116,"accession_number":"0001104659-23-086035","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Entrada Therapeutics gets UK authorization to start Phase 1 trial of ENTR-601-44 for Duchenne","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["UK MHRA and REC authorized Phase 1 CTIMP for ENTR-601-44 in healthy volunteers for exon 44 skipping Duchenne.","Phase 1 will enroll ~40 participants; primary endpoint safety, plus tolerability, PK, and exon skipping in muscle.","First participant expected to be dosed September 2023; data anticipated in second half of 2024.","Cash runway extended through end of 2025, supporting Duchenne franchise and broader intracellular therapeutics.","ENTR-601-44 is lead Duchenne product candidate for patients amenable to exon 44 skipping."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299864,"accession_number":"0001104659-23-069464","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Director Todd Foley resigns; stockholders elect Kim, Zeiher to board, ratify EY","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Todd Foley resigned from the Board effective June 7, 2023; no disagreement with company operations.","At 2023 Annual Meeting, Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. elected as Class II directors.","Votes: Kim 24,512,848 for, Zeiher 24,696,429 for; broker non-votes of 1,876,971 each.","Ratification of EY as independent auditor for FY2023 passed: 26,634,250 for, 606 against, 10 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299863,"accession_number":"0001689375-23-000036","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Q1 net loss $6.7M, cash $411.6M; advancing Duchenne pipeline despite clinical hold","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $411.6M at March 31, 2023, up from $188.7M at Dec 31, 2022.","Collaboration revenue from Vertex deal $25.3M in Q1; net loss improved to $6.7M from $21.7M in Q1 2022.","Vertex collaboration closed Feb 2023: $224M upfront + $26M equity; eligible for up to $485M milestones plus royalties.","ENTR-601-44 IND on clinical hold with FDA; pursuing global healthy volunteer trial initiation in 2023.","ENTR-601-45 selected as second Duchenne candidate; IND submission planned for Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":25260000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299862,"accession_number":"0001689375-23-000023","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Entrada Therapeutics appoints Dr. Bernhardt Zeiher to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8; Dr. Zeiher appointed as Class II director and to Nominating and Corporate Governance Committee.","Dr. Zeiher most recently served as Chief Medical Officer at Astellas Pharma; brings clinical and regulatory expertise.","Received initial option for 32,000 shares vesting over 3 years; annual director fee of $40,000 plus committee fee.","Entrada's lead programs include Duchenne muscular dystrophy and myotonic dystrophy type 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319957,"accession_number":"0001689375-23-000017","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada reports FY2022 net loss $94.6M; Vertex deal adds $224M upfront, extends cash into 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.6M Q4, $94.6M FY2022; R&D expenses $15.7M Q4, $66.6M FY2022.","Cash, equivalents & securities $188.7M at Dec 31, 2022; runway extended into 2H 2025 after Vertex deal.","Vertex collaboration closed Feb 2023: $224M upfront + $26M equity; up to $485M milestones plus royalties.","FDA clinical hold on ENTR-601-44 IND; company working to resolve, aiming for healthy volunteer trial in 2023.","Selected ENTR-601-45 for Duchenne exon 45 skipping; IND planned for Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319956,"accession_number":"0001689375-23-000008","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Entrada closes $224M upfront Vertex collaboration for DM1; cash runway to H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed global collaboration with Vertex for ENTR-701 and other DM1 research; Vertex leads development.","Received $224M upfront plus $26M equity investment at $16.26 per share (1,618,613 shares).","Eligible for up to $485M in research, development, regulatory, and commercial milestones.","Entitled to tiered royalties on future net sales of any products from the collaboration.","Proceeds extend cash runway into second half of 2025, funding DMD and other EEV programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319955,"accession_number":"0001689375-23-000003","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Entrada selects clinical candidate ENTR-601-45 for DMD exon 45 skipping; IND in H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ENTR-601-45 is an EEV-conjugated PMO targeting Duchenne patients amenable to exon 45 skipping.","In vivo data showed >90% exon skipping in skeletal muscle of hDMD mouse model after single IV dose.","More than 1,300 patients in US and Europe are exon 45 skipping amenable, per Entrada.","Company plans to submit IND application in second half of 2024.","Additional data expected at MDA Clinical & Scientific Conference in March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338134,"accession_number":"0001104659-22-128270","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Entrada receives FDA clinical hold on IND for ENTR-601-44 in Duchenne muscular dystrophy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Clinical hold placed on IND for ENTR-601-44, a potential treatment for DMD with exon 44 skippable mutations.","FDA to provide official clinical hold letter within 30 days; Entrada will work to address concerns.","No approved therapies exist for patients with exon 44 skippable mutations.","Entrada plans to share updates after further communications with the FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338133,"accession_number":"0001104659-22-125317","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Entrada licenses DM1 program to Vertex for $224M upfront, $26M equity, up to $485M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of ~$224M plus $26M equity investment; potential milestones up to $485M and tiered mid-to-high single-digit royalties on net sales.","Vertex gets exclusive worldwide license to ENTR-701 (late-stage preclinical) and other EEV-based DM1 candidates under 4-year research collaboration.","Entrada will continue pre-clinical work funded by Vertex; Vertex handles global development, manufacturing, commercialization.","Deal subject to HSR antitrust clearance; proceeds extend Entrada's cash runway into H2 2025.","Vertex agrees to purchase 1,618,613 shares at $16.26/share (105% of VWAP) in private placement; 2-year lockup with partial release after 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338132,"accession_number":"0001689375-22-000043","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Therapeutics reports Q3 2022 net loss of $25.1M; cash runway into H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $215.6M as of Sept 30, 2022, down from $291.1M at Dec 31, 2021.","Net loss for Q3 2022 was $25.1M, compared to $14.4M in Q3 2021.","R&D expenses increased to $19.0M (Q3 2022) from $10.5M (Q3 2021); G&A expenses rose to $7.0M from $3.9M.","On track to file IND for ENTR-601-44 (Duchenne exon 44 skipping) in Q4 2022; second IND for ENTR-701 (DM1) planned for H2 2023.","Preclinical data for ENTR-701 presented at World Muscle Society; collaboration entered with Myotonic Dystrophy Clinical Research Network."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355501,"accession_number":"0001689375-22-000010","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Therapeutics reports Q2 2022 net loss of $23.2M; cash runway into 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $244.3M as of June 30, 2022, sufficient into 2H 2024.","Net loss $23.2M vs $9.9M in Q2 2021; R&D $16.2M (up from $6.8M), G&A $7.3M (up from $3.1M).","On track to file IND for ENTR-601-44 (Duchenne) in Q4 2022; ENTR-701 named as first DM1 clinical candidate.","Appointed Karla MacDonald as Chief Corporate Affairs Officer.","Entered collaboration with Myotonic Dystrophy Clinical Research Network for natural history study."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373681,"accession_number":"0001104659-22-068101","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2022-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entrada Therapeutics stockholders elect three Class I directors, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dipal Doshi elected with 16,755,890 votes for, 1,330,767 withheld.","Kush M. Parmar elected with 13,773,852 votes for, 4,312,805 withheld.","Mary Thistle elected with 16,751,000 votes for, 1,335,657 withheld.","Ernst & Young LLP ratified as auditor with 18,307,689 votes for, 0 against.","All proposals passed; no other matters voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373680,"accession_number":"0001104659-22-059069","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["9.01","2.02"],"status":"ready","headline":"Entrada Q1 net loss $21.7M; announces second candidate ENTR-701 for DM1; IND on track for Q4 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2022 net loss of $21.7M vs $8.4M YoY; R&D expenses rose to $15.7M from $6.2M.","Cash, equivalents & marketable securities $263.9M at March 31 (down from $291.1M); runway into H2 2024.","Announced ENTR-701 as second clinical candidate for myotonic dystrophy type 1 (DM1).","On track to submit IND for ENTR-601-44 (Duchenne MD, exon 44 skipping) in Q4 2022.","Preclinical data showed durable exon 44 skipping in NHP biceps for at least 12 weeks after single dose of ENTR-601-44."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392374,"accession_number":"0001104659-22-036320","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Entrada Therapeutics signs 10-year lease for ~81,442 sq ft HQ in Boston","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for fifth and sixth floors of One Design Center Place, Boston; 10-year term with 5-year renewal option.","Initial base rent ~$525,417/month for first 12 months (based on 65,000 sq ft), then 3% annual increases for full 81,442 sq ft.","Landlord provides up to ~$19.5M tenant improvement allowance ($240/sq ft) and additional ~$1.63M contribution repayable over 10 years at 8% interest.","Rent commencement is earlier of occupancy or 10 months after delivery; expected delivery around April 1, 2022.","Security deposit of ~$3.95M in letter of credit; Landlord's Work includes pre- and post-delivery improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392373,"accession_number":"0001104659-22-033618","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada Therapeutics reports FY2021 net loss of $51.2M; cash at $291.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.4M in Q4'21 and $51.2M for FY2021, vs $8.7M and $26.5M in 2020.","Cash and equivalents $291.1M as of Dec 31, 2021, including $190.7M net from Nov 2021 IPO.","R&D expenses $12.4M in Q4 ($35.9M FY), up from $6.7M ($21.1M) YoY on preclinical studies.","On track to submit IND for ENTR-601-44 (DMD exon 44) in 2H 2022.","Appointed Jared Cohen, PhD, JD as General Counsel in January 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410710,"accession_number":"0001104659-21-147869","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2021-12-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Entrada reports Q3 2021 net loss $14.4M and closes $208.7M IPO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2021 was $14.4M vs $7.0M in Q3 2020; R&D expense $10.5M, G&A $3.9M.","Closed upsized IPO in November, raising $208.7M gross ($190.9M net) at $20.00 per share.","IPO included full exercise of underwriters' option for 1.36M additional shares; total shares issued 10.44M.","Cash position as of Sep 30, 2021 was $122.2M, excluding IPO proceeds; post-IPO cash significantly strengthened.","Lead candidate ENTR-601-44 for DMD advancing toward initial clinical data; DM1 program entering development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410709,"accession_number":"0001104659-21-132980","cik":1689375,"company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Entrada Therapeutics files amended charter and bylaws in connection with IPO","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorizes 150M shares of common stock and 10M shares of undesignated preferred stock.","Bylaws eliminate stockholder action by written consent, set procedures for proposals and nominations.","Changes previously disclosed in S-1; effective upon IPO consummation on November 2, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":256216081.4479638,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}